Csl Limited

Do Less Risky Stock Market Exposures Really Exist?

With a sense of raw panic descending on global stock markets, the question is whether there are any truly safe havens in terms of remaining exposed to equities?

“Well-Positioned” CSL Lifts H1 Earnings 11%

A rather ho-hum reaction from investors yesterday to another solid result from CSL, the current market darling and most expensive share on the ASX.

CSL Reaping The Reward Of Foresight

CSL has shown foresight in expanding plasma collection over recent years, enabling significant share in a market where demand for immunoglobulin has run ahead of supply.

Bullish CSL Hits Record High On Bumper FY19 Profit

CSL’s shares hit an all-time high yesterday after the company issued a bullish outlook statement on top of a very solid 2018-19 result and higher dividend (which was made a lot fatter by the slide in the value of the Aussie dollar in recent weeks).

If You Could Pick Just One Australian Stock For Your Portfolio, What Would It Be?

Global equities manager, WCM Investment Management (WCM), says the Australian company included in their international portfolio is one of their strongest performers over the past seven years – CSL Limited (ASX: CSL).

High Expectations Hurt CSL

Investors have been left cold despite CSL reporting an interim net profit of $US1.2 billion ($A1.7 billion), a higher dividend and a lift in full-year guidance.

CSL Confirms Guidance, Cans Share Split

CSL shares ended up 2.4% in yesterday’s general rally after CEO, Paul Perreault reaffirmed to the company’s AGM that the company was sticking to previous guidance for a 10-14% increase in annual net profit in 2018-19.

CSL In Rude Health Lifts Dividend 26%

CSL has lifted dividends to shareholders by a very sold 26% for the year to June 30 after reporting record sales and profits for the year to June.

CSL Provides Trifecta Of Good News

A trifecta of good news from blood products giant CSL yesterday in its 2017-18 first half report.

CSL Climbs To New High On Bullish Broker Upgrades

CSL shares hit a new all time high yesterday ahead of the release of its interim results in a fortnight’s time.

CSL Bets Big On Heart Attack Treatment

For pharmaceutical companies, spending hundreds of millions of dollars in drug trials is like a mining company investing in a new mine or mineral – investors don’t like the investment for the future and want more money, now.

Great Result Out Of CSL, So Is It Now A buy?

We reviewed the FY17 result for CSL Limited (ASX: CSL). Below are our summarised notes which readers may find useful, including our view on CSL.

CSL In US Expansion

At one stage in yesterday’s ‘blah’ market shares in blood products giant, CSL were up nearly 5% at $129.16 after it revealed plans to but a US biotech for more than $410 million, if certain performance markers are met over the next 8 years.

High Expectations Hurt CSL

The major report of the day yesterday came from the country’s premier healthcare and tech stock – CSL Ltd, but while the company out performed its guidance, it missed slightly on some analyst and market estimates and the shares were weaker.

CSL Soars On China Expansion Plans

Shares in CSL hit a new a record high of $137.65 yesterday after it made a big play to expand in the huge Chinese healthcare market via a $A460 million part acquisition.

CSL Lifts Profit By 12%

Blood products and vaccines group, CSL, is within a day’s rise of topping its all time high of $120.86 after rising $3.33, or 2.9% to $118 yesterday in the wake of the expected solid interim profit.

CSL Lifts Profit Forecast

Shares in blood products and vaccines giant CSL jumped by more than 12% yesterday after it surprised with a big earnings upgrade.

Bear Put Spread On CSL Limited

Today we are applying a Bear Put spread on CSL Limited (CSL) which has recently bounced from its short term downtrend line and showing bearish signals.

CSL Confirms Buyback

As expected Australia’s biggest pharma company, CSL will buy back up to $500 million worth of shares for the next year in what is now a regular occurrence.

Flu Vaccine Business Hits CSL

Shares in blood products group CSL fell 5% yesterday after it revealed an 18% slide in 2015-16 profit, plans to raise $US500 million in the US and run another big share buyback.

Could CSL Be Worth More Than $150 A Share?

CSL Limited (ASX: CSL) is a global developer and manufacturer of plasma-derived therapies for various diseases and disorders. We’ve blogged on CSL previously (see here) and for the most part, the story hasn’t changed. 

US Greenlights CSL Treatment

CSL is now such a dominant player in the global blood products markets (and a major presence on the ASX) that news of approval of a new potentially important product is big news indeed – more so than for many smaller companies.

CSL Profit Up 3.8%

CSL, Australia’s biggest pharmaceutical group, is paying an unchanged dividend after a slightly less than satisfying first half performance.

Back To Back Buybacks At CSL

Shares in blood and plasma giant CSL hardly reacted to confirmation yesterday from the company that it will launch a $1 billion share buyback, just months after completing the previous buyback (of $950 million).

Time to Sell CSL?

According to a report in the Financial Times this morning researchers in the US and the Netherlands claim to have made a breakthrough in the search for a universal flu vaccine.

One Offs Cloud CSL Result

Ignore the one-offs that cut CSL’s 2014-15 earnings growth.

CSL Hits $100…Again

Today CSL Limited (ASX: CSL) hit $100 for the second time in its history, the last time being that of September 2007 whereafter its stock split 3 for 1.

US FDA To Review CSL Treatment

CSL shares jumped more than 1.6%, or close to $1.58 yesterday after the company revealed that US drug regulators will review the company’s latest treatment for the blood disease haemophilia after a clinical trial showed promising results.

Should You Buy CSL?

CSL Limited’s (ASX: CSL) share price has strengthened in recent years (appreciating from below $30 to over $90), supported by the firm’s consistent approach to dividend policy and a steady commitment to share buybacks.

CSL Shares Hit By Earnings Slowdown

Blood plasma and vaccine producer CSL took a whacking yesterday after it warned despite double-digit sales growth in the first half for its albumin and specialty products businesses, growing competition would see full year earnings crimped.

A Bargain Buy

The best investments are those you can pick up for a bargain, but not because the shares get slammed amid a short-term setback. The very best are those that trade at a discount to intrinsic value for a long time, because nobody notices or cares. CSL Limited (ASX: CSL) is one of those unexciting businesses that even owners of so-called ‘blue-chip’ portfolios only hold occasionally.

CSL Continues To Spend Big

Australia’s CSL Ltd (CSL), the world’s largest blood products company, said says it has agreed to buy Novartis AG’s global influenza vaccine business for $US275 million.

New CSL Buyback To Reward Shareholders

Shareholders in blood plasma product and vaccine maker CSL will have the joys of having to decide whether to take part in yet another share buyback – the seventh in eight years.

CSL Plans For Expansion

CSL has announced a $450 million investment to expand its global production capacity.

CSL Promises Another Big Year

More of the same from the past couple of years is promised for the coming year from Australia’s global pharmaceutical giant, CSL – a solid profit rise, higher dividend, with another buyback also possible.

Long-Term Value

At Montgomery Investment Management, we invite our clients to invest with us if their investment philosophy is aligned with our own. In our opinion, it takes time to realise value, and discipline is required to maintain confidence in the investment process amidst short-term volatility. This view is also shared by CSL.

CSL Optimistic Of Continued High Demand

Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.574 billion.

CSL’s Next Gen A Blood Curdler

Attending the CSL research and development day can feel like being in a molecular biology lecture. But the presentations are a reminder why CSL’s management deserves respect. Though unmistakably scientists, they’re a rare breed – scientists with business acumen.

CSL Reveal New $950 Million Buyback

Shares in CSL closed up 1.3% yesterday at $66.26 as shareholders showed their appreciation of the company’s 7th share buyback which could total up to $950 million.

CSL Posts 19% Net Profit Boost

CSL was another major company whose shares were sold down yesterday, despite the group reporting a very solid full year profit and a higher dividend.

CSL And The Swiss Franc

Back in 1978 the German economy was in a sorry state and funds were flowing steadily out of the German mark and into the safety of the Swiss franc. It was also a time anyone who was anyone, by whatever means, held a secret Swiss bank account, further increasing the popularity of the neutral country’s currency. The subsequent strength in the Swissy forced Switzerland’s central bank, the Swiss National Bank, to intervene to cap the currency and prevent the erosion of Switzerland’s export industry, including tourism. Famously, the intervention was a disaster.

Is CSL A Master Of Share Buy Backs?

When a company buys back its shares, the announcement is often accompanied by reports suggesting either 1) the company has no other growth options towards which it can employ equity capital or, 2) the company has great confidence in its future and other shareholders should be following its lead rather than selling out to the company itself.

Profits: Strong Dollar Hits CSL Interim, Again

CSL has again seen profits hit by the strong Australian dollar, yesterday forecasting a 10% fall in full year earnings based on current exchange rates.

A Temporary Boost For CSL

Late last week the European Mediciness Agency recommended the suspension of Octapharma’s market authorisation for its IVIG compound octagam through Europe, while the company has also initiated a voluntary recall of the same compound in the US market.

Profits; CSL Down Despite New Buyback, Higher Payout

Australia’s biggest drug company, CSL Ltd, seems to have run out of ideas for new investment, so it is going for another buy back offer to shareholders of up to $900 million.

CSL Gaining At Baxter’s Expense

Last week Baxter of the US reported a 5% revenue decline for its Bioscience division, within which plasma products recorded growth of 3% compared to the previous corresponding period. The company indicated the overall result showed some market share losses in the Antibody Therapy (IVIG) market in the US, lower albumin sales in that market and delays or lost tenders related to Recombinants (pdFVIII).

Latest US Plasma Data Add To More Doubt On CSL

As noted by Credit Suisse, key plasma market data in the US showed some improvement in May. The numbers showed IVIG volume growth increased to 3.4% on a 12-month rolling basis. This compares to 2.7% growth in April and is the largest monthly increase since September of last year.

CSL To Benefit From Consolidation In US Blood Products Sector

Blood products group CSL (CSL) has been involved in attempts at industry consolidation via a previous failed bid for competitor Talecris, but this time it will be watching from the sidelines as Grifols of Spain has reached agreement to acquire Talecris for US$3.4 billion.

Is CSL’s Earnings Risk To The Downside?

The FNArena database shows a 6:4 split in terms of Buy and Hold ratings for blood products group CSL (CSL), most of the positive views based on expectations of strong earnings growth in coming years.

CSL’s Trifecta; Profit, Dividend, Shares Up

Shares in CSL Ltd, the country’s major pharmaceutical group, rose strong yesterday after a bullish outlook from the company and CEO Brian McNamee.

Reduced US Swine Flu Order Has Little Impact On CSL

Recent data suggest Americans are not making it a priority to take swine flu shots in the amount that had been expected, an outcome that has seen the US Government reduce its H1N1 or swine flu order with CSL (CSL) from 36 million doses to just 14 million doses, with the change having a corresponding impact on group earnings.

CSL Feels Dollar’s Gains

CSL’s Strong Year

Where’s The Value In CSL?

A solid result with few surprises is the general broker reaction to the full year profit announcement of flu vaccine and blood products group CSL (CSL), as net profit of $1,145.9 million broadly met or slightly exceeded most estimates in the market.

Could CSL Disappoint On Expectations?

In the FNArena database CSL (CSL) scores eight Buy ratings out of a possible ten along with two Hold recommendations, which clearly indicates most of the market sees good value in the stock at current levels even allowing for the disappointment of the company having to abandon its takeover bid for US group Talecris.

CSL Cans US Bid, To Return Cash In Buyback

CSL To Buy Back Shares, Abandons Talecris Deal

Blood plasma producer CSL (CSL) has announced it will buy back close to 55m of its own shares or about 9% of all outstanding shares after it and US based Talecris decided it was best to abandon their intended merger given US authorities’ blockage of the deal.

Could CSL Still Win Talecris?

The immediate reaction to the news the FTC in the US had decided to oppose CSL’s (CSL) proposed takoever of Talecris was for price targets on the stock to be cut given anticipated earnings gains from the deal were being removed from broker models. However, according to Southern Cross Equities healthcare analyst Stuart Roberts there is still a chance the company will win out in court.

CSL To Challenge US No To Deal

No Love Lost For CSL Post Talecris Rejection

As mentioned by FNArena yesterday (See: No Talecris No Reason To Be Negative On CSL, 26/05/09) Bank of America-Merrill Lynch had yet to update its views on CSL (CSL) after it became apparent the company’s proposed acquisition of Talecris in the US would not be approved by regulators. The broker has now rectified the situation, with the good news for shareholders being BA-ML still considers the stock to be a Buy.

CSL’s US Ambitions Hit Major Roadblock

No Talecris No Reason To Be Negative On CSL

For several months the potential big upside case for blood products group CSL (CSL) has been its proposed takeover of Talecris in the US as this would give it a strong competitive position in that market as well as delivering significant cost synergies and driving what is already a healthy earnings growth outlook.

It’s Swine Flu Potential Against Talecris Stumbles For CSL

With swine flu reaching Australian shores the Federal Government has acted in lifting the alert level related to the virus to "contain", meaning measures will be taken to limit the spread of the disease. The next phase is "sustain", which would entail ensuring there were enough medicine available to sustain a response until a customised pandemic vaccine was available.

CSL Not Only About Talecris Potential

One Australian company that hasn’t enjoyed the recent rally in equity markets is blood products group CSL (CSL), with Southern Cross Equities analyst Stuart Roberts suggesting market concerns over possible oversupply of IVIG and the regulatory outcome of the group’s proposed acquisition of Talecris in the US have combined to weigh on the share price.

CSL Aiming For $1 Billion Net Profit

CSL Sees 2009 Earnings Higher